Eintrag weiter verarbeiten
Immune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma
Gespeichert in:
| Zeitschriftentitel: | CA: A Cancer Journal for Clinicians |
|---|---|
| Personen und Körperschaften: | |
| In: | CA: A Cancer Journal for Clinicians, 68, 2018, 3, S. 178-179 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Fillon, Mike Fillon, Mike |
|---|---|
| author |
Fillon, Mike |
| spellingShingle |
Fillon, Mike CA: A Cancer Journal for Clinicians Immune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma Oncology Hematology |
| author_sort |
fillon, mike |
| spelling |
Fillon, Mike 0007-9235 1542-4863 Wiley Oncology Hematology http://dx.doi.org/10.3322/caac.21423 <jats:title>Key Points</jats:title><jats:p> <jats:list list-type="bullet"> <jats:list-item><jats:p>When compared with docetaxel, checkpoint inhibitors prolong overall survival in second‐line and later lines of treatment among patients with advanced NSCLC.</jats:p></jats:list-item> <jats:list-item><jats:p>There was no significant increase in survival noted for patients with <jats:italic>EGFR‐</jats:italic>mutant tumors. Checkpoint inhibitors should be considered for these patients only after all other effective therapies have been tried.</jats:p></jats:list-item> <jats:list-item><jats:p>Smoking status appears to have minimal effect on the relative efficacy of these 2 therapies.</jats:p></jats:list-item> </jats:list></jats:p> Immune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma CA: A Cancer Journal for Clinicians |
| doi_str_mv |
10.3322/caac.21423 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMzMyMi9jYWFjLjIxNDIz |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMzMyMi9jYWFjLjIxNDIz |
| institution |
DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Zi4 DE-Gla1 DE-15 DE-Pl11 DE-Rs1 DE-14 DE-105 DE-Ch1 DE-L229 DE-D275 |
| imprint |
Wiley, 2018 |
| imprint_str_mv |
Wiley, 2018 |
| issn |
0007-9235 1542-4863 |
| issn_str_mv |
0007-9235 1542-4863 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
fillon2018immunecheckpointinhibitorsaresuperiortodocetaxelassecondlinetherapyforpatientswithnonsmallcelllungcarcinoma |
| publishDateSort |
2018 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
CA: A Cancer Journal for Clinicians |
| source_id |
49 |
| title |
Immune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma |
| title_unstemmed |
Immune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma |
| title_full |
Immune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma |
| title_fullStr |
Immune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma |
| title_full_unstemmed |
Immune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma |
| title_short |
Immune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma |
| title_sort |
immune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma |
| topic |
Oncology Hematology |
| url |
http://dx.doi.org/10.3322/caac.21423 |
| publishDate |
2018 |
| physical |
178-179 |
| description |
<jats:title>Key Points</jats:title><jats:p>
<jats:list list-type="bullet">
<jats:list-item><jats:p>When compared with docetaxel, checkpoint inhibitors prolong overall survival in second‐line and later lines of treatment among patients with advanced NSCLC.</jats:p></jats:list-item>
<jats:list-item><jats:p>There was no significant increase in survival noted for patients with <jats:italic>EGFR‐</jats:italic>mutant tumors. Checkpoint inhibitors should be considered for these patients only after all other effective therapies have been tried.</jats:p></jats:list-item>
<jats:list-item><jats:p>Smoking status appears to have minimal effect on the relative efficacy of these 2 therapies.</jats:p></jats:list-item>
</jats:list></jats:p> |
| container_issue |
3 |
| container_start_page |
178 |
| container_title |
CA: A Cancer Journal for Clinicians |
| container_volume |
68 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792334381709262855 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T14:27:45.078Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Immune+checkpoint+inhibitors+are+superior+to+docetaxel+as+second%E2%80%90line+therapy+for+patients+with+non%E2%80%90small+cell+lung+carcinoma&rft.date=2018-05-01&genre=article&issn=1542-4863&volume=68&issue=3&spage=178&epage=179&pages=178-179&jtitle=CA%3A+A+Cancer+Journal+for+Clinicians&atitle=Immune+checkpoint+inhibitors+are+superior+to+docetaxel+as+second%E2%80%90line+therapy+for+patients+with+non%E2%80%90small+cell+lung+carcinoma&aulast=Fillon&aufirst=Mike&rft_id=info%3Adoi%2F10.3322%2Fcaac.21423&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792334381709262855 |
| author | Fillon, Mike |
| author_facet | Fillon, Mike, Fillon, Mike |
| author_sort | fillon, mike |
| container_issue | 3 |
| container_start_page | 178 |
| container_title | CA: A Cancer Journal for Clinicians |
| container_volume | 68 |
| description | <jats:title>Key Points</jats:title><jats:p> <jats:list list-type="bullet"> <jats:list-item><jats:p>When compared with docetaxel, checkpoint inhibitors prolong overall survival in second‐line and later lines of treatment among patients with advanced NSCLC.</jats:p></jats:list-item> <jats:list-item><jats:p>There was no significant increase in survival noted for patients with <jats:italic>EGFR‐</jats:italic>mutant tumors. Checkpoint inhibitors should be considered for these patients only after all other effective therapies have been tried.</jats:p></jats:list-item> <jats:list-item><jats:p>Smoking status appears to have minimal effect on the relative efficacy of these 2 therapies.</jats:p></jats:list-item> </jats:list></jats:p> |
| doi_str_mv | 10.3322/caac.21423 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMzMyMi9jYWFjLjIxNDIz |
| imprint | Wiley, 2018 |
| imprint_str_mv | Wiley, 2018 |
| institution | DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-105, DE-Ch1, DE-L229, DE-D275 |
| issn | 0007-9235, 1542-4863 |
| issn_str_mv | 0007-9235, 1542-4863 |
| language | English |
| last_indexed | 2024-03-01T14:27:45.078Z |
| match_str | fillon2018immunecheckpointinhibitorsaresuperiortodocetaxelassecondlinetherapyforpatientswithnonsmallcelllungcarcinoma |
| mega_collection | Wiley (CrossRef) |
| physical | 178-179 |
| publishDate | 2018 |
| publishDateSort | 2018 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | CA: A Cancer Journal for Clinicians |
| source_id | 49 |
| spelling | Fillon, Mike 0007-9235 1542-4863 Wiley Oncology Hematology http://dx.doi.org/10.3322/caac.21423 <jats:title>Key Points</jats:title><jats:p> <jats:list list-type="bullet"> <jats:list-item><jats:p>When compared with docetaxel, checkpoint inhibitors prolong overall survival in second‐line and later lines of treatment among patients with advanced NSCLC.</jats:p></jats:list-item> <jats:list-item><jats:p>There was no significant increase in survival noted for patients with <jats:italic>EGFR‐</jats:italic>mutant tumors. Checkpoint inhibitors should be considered for these patients only after all other effective therapies have been tried.</jats:p></jats:list-item> <jats:list-item><jats:p>Smoking status appears to have minimal effect on the relative efficacy of these 2 therapies.</jats:p></jats:list-item> </jats:list></jats:p> Immune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma CA: A Cancer Journal for Clinicians |
| spellingShingle | Fillon, Mike, CA: A Cancer Journal for Clinicians, Immune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma, Oncology, Hematology |
| title | Immune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma |
| title_full | Immune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma |
| title_fullStr | Immune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma |
| title_full_unstemmed | Immune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma |
| title_short | Immune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma |
| title_sort | immune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma |
| title_unstemmed | Immune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma |
| topic | Oncology, Hematology |
| url | http://dx.doi.org/10.3322/caac.21423 |